The recent discovery of long term AIDS nonprogressors who harbor nef-attenuated HIV suggests that a naturally occurring live vaccine for AIDS may already exist. Animal models have shown that a live vaccine for AIDS, attenuated in nef, is the best candidate vaccine. There are considerable risks, real and perceived, with the use of live HIV vaccines. We have introduced a conditional lethal genetic element into HIV-1 and simian immunodeficiency virus (SIV) molecular clones deleted in nef. The antiviral strategy we employed targets both virus replication and the survival of the infected cell. The suicide gene, herpes simplex virus thymidine kinase (tk), was expressed and maintained in HIV over long periods of time. Herpes simplex virus tk confers sensitivity to the antiviral activity of acyclic nucleosides such as ganciclovir (GCV). HIV-tk and SIV-tk replication were sensitive to GCV at subtoxic concentrations, and virus-infected cells were eliminated from tumor cell lines as well as primary cell cultures.
Live attenuated vaccines have been used successfully since the 1700s. The eradication of smallpox was made possible by improvements of the live vaccine originally tested by Jenner in 1796. Forty years ago a strategy to develop a vaccine against polio was realized after discovering some individuals who harbored attenuated virus (1) . Since the development of the polio vaccine, many successful vaccines have been created by using attenuated viruses, including the newly developed chicken pox immunization, which contains live varicella-zoster virus (2) . A live attenuated vaccine for AIDS has been proposed (3) based on virus deleted in nef (4) . Such a vaccine has been found to be safe and effective in adult Rhesus monkeys (5) . However, the vaccine strain when inoculated orally into newborn macaques was recently shown to be pathogenic (6) . The pathogenicity of attenuated AIDS virus in newborns may be related to the route of inoculation; it remains to be determined if nef-attenuated viruses acquired in utero are also pathogenic.
Nef may also be associated with pathogenesis in HIV infection of humans. Recently individuals harboring HIV for long periods of time without any signs of AIDS were shown to be infected with nef-deleted virus (7, 8) . These individuals may be naturally vaccinated. Additionally, a child studied by Bryson and coworkers (9) became infected in utero and has subsequently cleared the virus, raising the possibility that the child may have been initially infected with an attenuated strain. Nevertheless, the results with the neonate model raise the standard of acceptable risk associated with live attenuated vaccines for AIDS (10) , and the need for the development of a safer vaccine exists.
Retroviruses have the potential of promoting tumors by insertional oncogenesis. Proviral insertion upstream of a proto-oncogene can result in up-regulation of that gene through transcriptional promotion by viral long terminal repeats. Recently several groups have observed an association of HIV-1 sequence with B-cell lymphoma (11, 12) . McGrath and coworkers (12) have studied tumors from a number of individuals and have determined that HIV-1 was clonally integrated upstream of the c-fes/fps proto-oncogene. Additionally, they showed that both HIV-1 antigen and oncogene antigen were present in the tumor (12) . A Rhesus monkey infected with simian immunodeficiency virus (SIV) deleted in nef developed B-cell lymphoma; however, in this case the lymphoma was not associated with SIV insertion (13) . A live attenuated vaccine has the potential of promoting tumors through insertional oncogenesis; therefore, a significant improvement to this vaccine would be the ability to eliminate the vaccine strain and the cells it infects.
The control of viruses in the herpes family can be affected with the use of acyclic nucleoside analogs, such as ganciclovir (GCV) or acyclovir (14, 15) . The susceptibility of such viruses to the drugs maps to a viral thymidine kinase (tk) gene (UL97) (16) . tk is conserved in the a, ,B, and y classes of herpes viruses, and it shows a preference for GCV {9-[(1,3-dihydroxy-2-propoxy)methyl]guanine} or acyclovir over its normal substrate thymidine or guanine. The specificity of GCV derives from the fact that it is not efficiently phosphorylated by mammalian tks (16) . Once phosphorylated, the analog will become incorporated into newly synthesized DNA and terminate chain elongation, killing the transduced cell. This conditional lethal genetic element has been proposed and used as a negative gene therapy. Thymidine kinase delivered by viral vectors, followed by treatment with nucleoside analogs, has been used successfully as a treatment for neoplastic diseases (17) (18) (19) (20) (21) as well as to control cell proliferation in response to vascular damage (22) . The strategy has also been employed as a valuable tool to delete developmentally programmed cell lineages in a transgenic animal, by fusing tk to an appropriate promoter (23, 24) . Many of the examples have successfully employed retroviral vectors to deliver the tk gene.
The addition of a conditional lethal marker to the live attenuated vaccine strain should enable additional control of virus load in the infected individual and perhaps allow the elimination of the vaccine strain. The generation of escape mutants is a critical issue in this strategy. The generation of mutations that inactivate tk are a likely consequence of retroviral replication, since even in the herpes virus genome, GCV-resistant mutants can occur despite the presence of a positive selective force (25, 26) .
METHODS
Construction ofHIV-tk and SIV-tk. HIV-tk was constructed from full-length pHIVNL4-3 by first removing 272 bases from nef and installing unique XbaI and XhoI restriction endonuclease recognition sites in the deletion joint, and then tk from Abbreviations: SIV, simian immunodeficiency virus; GCV, ganciclovir; tk, thymidine kinase; PBMC, peripheral mononuclear cells; HSV-1, herpes simplex virus type 1. *e-mail: kestleh@cesmtp.ccf.org.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. 9811 herpes simplex virus type 1 (HSV-1) was amplified using oligonucleotides having XbaI and XhoI restriction sites at the N terminus and C terminus of tk, respectively (27) . tk from HSV-1 (29) was amplified with oHSV13as encoding an XhoI site and oHSV14s encoding an XbaI site, and this product and the nef deletion molecular-cloned virus (HIVnef-deletion) were digested with XbaI and XhoI and ligated together to form HIV-tk.
SIV-tk was constructed by deleting the upstream U3 region overlapping nef of pSIVmac239/nef-deletion (4) . Nucleotides 9916-10087 (28) were removed by cleavage with NsiI and Stul. The ends were made flush with T4 DNA polymerase and ligated generating p239nef-deletion/U3-deletion. The removal of the 172 upstream U3 sequence was confirmed by DNA sequencing. The plasmid was further shortened by removal of 1592 nucleotides from the 3'-flanking cellular sequences, by deletion of a BstE2-BstBI fragment.
The two ATG start codons in the remaining portion of Nef reading frame and two ATG codons in the -2 reading frame preceding the site used for the insertion of tk were mutated without changing the overlapping env amino acid sequence in the -1 reading frame by PCR mutagenesis. Oligonucleotide oSIViOls and oSIV102as were used as primers to amplify a segment of SIVmac239 (28) . The product was purified to remove oligonucleotides and was used as a primer in a second amplification with oSIV103s using SIVmac239 as a template. The product was cleaved with restriction sites SstI and NcoI and inserted in place of the SstI-NcoI fragment of SIVmac239, and the region containing the fragment was completely sequenced to assure the presence of the mutations and that no other unwanted mutations were introduced. This template was used to introduce the mutations into the two ATG codons in the -2 reading frame. The final clone having all four ATG codons mutated was constructed in two parts. The first segment was made by amplifying SIVmac239 with oSIV104s and oSIV102as. This product was purified and used with oSIV103s to amplify an NcoI-SstI fragment using the previously generated SIVmac239 having two mutations in the nef reading frame ATG. The fragment containing all four mutations was used to replace the SstI and NcoI of SIVmac239, and once again the region containing the fragment was completely sequenced to assure the presence of the mutations and that no other mutations were introduced during mutagenesis or cloning.
HSV-1-tk was amplified in two overlapping segments to mutate internal SphI and SacI sites while maintaining the tk reading frame. The N-terminal segment was amplified with oHSV20s containing the SIVnef Kozak translational initiation sequence and oHSV9as generating a fragment without the Sacl site, at position 449 from the tk start (29) . This product, fresh tk template and oHSVl5as, were subjected to a second amplification to generate a full-length tk with SacI sites on the 5' and 3' ends. This template was further amplified with oHSV1Os and oHSVl5as to mutate the SphI site at position 392 from the tk start (29) . That product, along with oHSV20s and a full-length tk template, was extended to incorporate both the Sacl and SphI site mutants, as well as the Sacl adapters on the termini and was sequenced. p239nef-deletion/US-deletion and the adapted tk were cleaved with Sacl and ligated together to form SIV-tk. Oligonucleotides were commercially obtained from Operon. Restriction enzymes ligase and amplification reagents were obtained from New England Biolabs and Boehringer Mannheim.
PCR Determination of Proviral TK. Total cellular DNA was prepared as described previously (27) . Primer pairs oSF28626s and oSF29491as (27) as well as oHSV13as and oHSV14s (29) were used to amplify proviral DNA. Taq polymerase was obtained from Perkin-Elmer/Cetus and was used according to the recommendations of that manufacturer. The sequence of the tk gene from the PCR clones was determined by the dideoxy method using reagents from Amersham using oHSV14s-, oHSV13as-, oHSVlOs-, and oHSV9as-specific primers as well as the T7 universal primer and the sp6 universal primer.
Virus and Cells. Jurkat and CEMx174 cells were maintained in RPMI 1640 media supplemented with 10% fetal calf serum and GCV, where indicated. Fresh media was added every 2 days, and the GCV was replenished to account for its half-life. Peripheral mononuclear cells (PBMC) were prepared from the whole blood of HIV seronegative donors by separating on Ficoll-Hypaque (Organon). Cells were washed in sterile PBS and suspended in RPMI 1640 medium containing 20% fetal bovine serum (HyClone) 1% penicillin-streptomycin, Lglutamine, Hepes, 10 units/ml interleukin 2 (Chiron), and 4 ,ug/ml phytohemagglutinin-P (Sigma). Cells were incubated at 37°C in 5% CO2 for 48 h and then washed in PBS and resuspended in RPMI 1640 supplemented as described above omitting the PHA-P. HIV-tk molecular clone was introduced into Jurkat cells and human PBMC using lipofectamine (GIBCO/BRL). p239/tk-SpE3' encoding the 3'-half of the SIV genome and p239SpSp5', the 5'-half molecular clone, were cleaved with SphI, ligated together, and transfected into CEMx174 as described previously (30) . Infection of Jurkat and PBMC was accomplished by centrifugation of 5 x 106 cells and incubation with 50,000 RT units or 5000 pg of p24 gag antigen units for 2 h at 37°C 5% CO2. Cells were washed with serum-free media and diluted to 1 x 106 cells/ml in RPMI 1640 medium with 10% fetal bovine serum. Reverse transcriptase activity was determined by [3H]dTTP (DuPont/NEN) incorporation on a poly(rA) template primed with oligo(dT)12 18 (Pharmacia) according to the conditions described by Johnson et al. (31) . HIV gag antigen determination was accomplished with reagents from Coulter. CEMx174 and Jurkat cell viability were determined by trypan blue exclusion. Cells were cultured in RPMI 1640 medium containing 10% fetal bovine serum and the indicated concentration of GCV. The number of viable cells, at the day indicated, were determined by counting a diluted suspension with a hemocytometer.
Cos-1 cells were transfected with 5 ,ug of salmon sperm DNA, pNL4-3Anef (HIVnef-deletion), or pHIV-tk by lipofection and 48 h later were lysed as described below.
Expression of Thymidine Kinase in Infected Cells. Cells indicated were lysed with RIPA buffer (32) , and 50 jig were electrophoresed on a 10% SDS polyacrylamide gel. The gel was electroblotted onto nitrocellulose using a Bio-Rad Mini Trans-Blot cell under conditions described by that manufacturer. The membrane was blocked by incubating with 5% nonfat dried milk in PBS containing 0.02% Tween 20 (PBS-T) (Bio-Rad) for 2 h at room temperature and then washed with PBS-T. A mixture containing 1% nonfat dried milk in PBS-T and a 1:1000 dilution of rabbit antiserum raised against a synthetic peptide (a gift from KT-Jeang) was added to the blot and incubated for 1 h, at room temperature. The blot was rinsed with PBS-T two times, washed once with PBS-T for 15 min, and washed four times in PBS-T for 5 min. The signal was generated by reacting the blot conjugated with the primary antibody, with a 1:10,000 dilution of goat anti-rabbit antibody conjugated with horseradish peroxidase and 1% nonfat dried milk in PBS-T for 1 h, at room temperature. The blot was rinsed with PBS-T two times, washed once with PBS-T for 15 min, and washed four times in PBS-T for 5 min. Visualization was accomplished with the Enhanced Chemiluminescence reagent kit (Amersham).
RESULTS
The tk gene of HSV-1 was subcloned into the nefreading frame of HIV (Fig. 1A) . The vaccine strain HIV-tk was constructed from molecular cloned HIV pNL4-3 in which the nef reading frame was completely eliminated. HIV-tk molecular cloned 4) and day 14 (lanes 2 and 5) . In lanes 1-3, the primers oSF28626s and oSF29491as are used. oSF28626s is homologous to a region 150 nucleotides upstream of tk, and oSF29491as represents the sequence 400 nucleotides downstream of tk. In lane 3, the same primers are used to amplify water. The tk gene was also amplified from both day 8 and day 12 proviral DNA using oHSV14s and oHSV13as corresponding to the 5' and 3' ends of the gene. A water control using this primer pair was also negative. (Fig. 1B) .
SIV encoding a tk reading frame fused to the first 58 amino acids of the nef gene was stably expressed for long periods of time but was not sensitive to the GCV treatment (data not shown). SIV encoding tk without nef sequence (SIV-tk) was constructed by mutating two in-frame and two out-of-frame start codons in nef while preserving the content of the overlapping envelope reading frame (Fig. 1A) . A Kozak translation initiation sequence (33) (GCCACCATGG) was installed preceding the tk gene to ensure efficient translation.
The toxicity of GCV was assessed in CEMx174, Jurkat cell lines, and human PBMC by measuring the relative number of viable cells after incubation for over 20 days, with various concentrations of the drug. No significant effect on cell viability or cell growth was observed for GCV concentrations at or below 20 ,tg/ml, although PBMC grew poorly at 20 ,ug/ml GCV. All cell types experienced a dramatic reduction in cell viability when grown in media containing GCV concentrations tested above 20 ,ug/ml (Fig. 2) .
Proc. Natl. Acad. Sci. USA 93 (1996) The effect of GCV concentration on the replication of HIV-tk was assessed by measuring HIV p24 antigen produced in the supernatant of Jurkat-infected or PBMC-infected cells. The growth of the HIV-1 encoding a HSV-tk in Jurkat was delayed relative to that of HIVNL4-3/nef-deletion, the virus from which it was derived. Ganciclovir at 10 and 20 gg/ml in the culture media had no effect on control virus HIVNL4-3/ nef-deletion replication in Jurkat. In contrast, the virus encoding a HSV-tk gene in place of nef was able to replicate in Jurkat cells treated with GCV at 10,g/ml but was unable to replicate in cells growing in medium containing GCV at 20 ,ug/ml (Fig. 3) . The growth of HIV-tk was slightly delayed at 10,ug/ml GCV, but the rate of virus production was similar to untreated and control virus. However, HIV-tk was completely inhibited by 20 ,tg/ml GCV (Fig. 3) , and we were unable to recover any HIV-tk from the supernatant of day 19 culture treated with 20 ,tg/ml GCV (data not shown).
The ability of HIV-tk to replicate in human primary lymphocytes was tested. No difference was observed between HIV-tk and HIVNL4-3/nef-deletion replication when grown in PBMC without GCV (Fig. 4) . However, HIV-tk replication was more sensitive to GCV treatment in these primary lymphocytes. No HIV-tk replication was seen in phytohemagglutinin-P-stimulated PBMC treated with 10 pLg/ml (Fig. 4) . The replication of HIVnef deletion was only modestly affected by this concentration of GCV. The replication of both viruses was diminished by the presence of GCV at 20 ,ug/ml, but, while HIVnef-deletion was able to show some production of virus at this concentration, the replication of HIV-tk was profoundly inhibited by 20,ug/ml GCV. To test for the elimination of virus from the infected culture, we removed GCV from the media at day 18 and maintained the culture for an additional 22 days.
Virus did not spread from either the 10 or the 20 ,ug/ml GCV-treated cultures (Fig. 4) .
The stability of the tk gene as a function of growth in subinhibitory concentrations of GCV was determined. Jurkat cells infected with HIV-tk were cultured in media containing no GCV for 19 days. Virus was then used to infect fresh Jurkat cells in media containing 10 ,ug/ml GCV, a concentration in which virus replication is only minimally affected (Fig. 3) . Virus from day 34 was used to infect fresh Jurkat cells, the culture was split, and half was treated with 20 ,tg/ml GCV while no drug was added to the other half (Fig. 5) . A significant fraction of the virus obtained from cells treated with GCV at subinhibitory concentrations remained sensitive to the drug, as shown by the extent and kinetics of virus replication (Fig. 5 Middle Right). The wild-type tk sequence was maintained for at least 42 days, even after culturing in subinhibitory concentrations of GCV (Fig. 5 Middle Left and Bottom). A 778-nucleotide deletion in tk was observed in provirus from the culture shifted up to 20 ,ug/ml GCV at day 48. Deleted virus was not detected in the provirus from cultures that were shifted to no GCV at both times tested: day 42 or day 48 cultures (Fig.  5 Middle Left).
SIV-tk was tested for its sensitivity to GCV by transfecting into CEMx174, incubating without drug for 3 days, and dividing the culture into two halves: one containing 20 ,mg/ml GCV and the other without the drug. SIV-tk replication was markedly reduced in the presence of 20 gg/ml GCV while the replication of SIVnef-deletion was indistinguishable from the untreated control culture (Fig. 6 ). (35) .
DISCUSSION
The purpose of the experiments described in this study was to attempt to gain further control of virus load in the nef- attenuated background. Ideally, the live inactivatable vaccine would be available for use in adults and would be employable in the neonate, to control accidental and maternal transmission. The safety of GCV use in neonates and infants is well documented (36, 37) . The molecular cloned viruses described above will also serve as intermediates for future gene therapies that employ a conditionally lethal delivery virus.
The total elimination of virus in vivo will require eradication of virus from all compartments within the individual. The ability to eliminate infected cells with GCV therapy is depen- antigen was determined for HIV-tk pretreated with 10 ,Lg/ml GCV (day 19) and then shifted to the presence of 20 ,ug/ml GCV (solid diamonds) or no GCV (open diamonds) (Middle Left). The tk gene was examined from the proviruses obtained from cultures at day 42 and day 48 in the presence and absence of 20 ,ug/ml GCV by PCR. The complete sequence was determined for six clones from day 42 shifted up to 20 ,ug/ml GCV, three clones from the day 42 culture shifted down to no GCV, and one clone from day 48 culture shifted up to 20 ,ug/ml GCV. dent on cell division, specifically DNA synthesis. HIV-1 is able to replicate in nondividing macrophages; therefore, it follows that the total elimination of virus should not be possible in this cell type. However the vaccine strains used in this study (derived from SIVmac239 and HIV-NL4-3) are T-cell tropic clones that do not infect macrophages in vitro (4, 38, 39) . The emergence of macrophage tropic virus from animals infected with T-cell tropic SIVmac239 can be observed with time (40) . The viruses used to construct the vaccine are nef-deficient, and the emergence of macrophage tropic viruses from animals infected with SIV deleted in nef has not been reported. nef has also been implicated as a positive factor for macrophage growth (41, 42) . We predict that the virus loads will be reduced substantially, as was observed for SIVmac239/nef-deletion and that the emergence of macrophage tropic SIV-tk will not occur. While the elimination of infected macrophages may not be possible, the replication of HIV and SIV in infected macrophages will be sensitive to GCV therapy. Since the replication of primate lentiviruses requires proviral DNA synthesis (43, 44 ) GCV treatment will stop new infections of macrophages while treatment is ongoing. Reverse transcriptase or protease inhibitors can also be used to halt production of virus from the previously infected population of macrophages.
We expected the propagation of tk in lentiviral vectors to result in the rapid generation of escape mutants. The generation of escape mutants can occur even when tk is propagated in herpes viruses, which replicate with greater fidelity than HIV-1 (45) . However, the results of Figs. 3 and 4 demonstrate that the candidate HIV-1 live inactivatable attenuated vaccine strain was completely unable to replicate in GCV, and the results of Fig. 5 show that despite extended time in culture and growth in the presence of concentrations of GCV having low or no antiviral activity, HSV-tk persisted and was functional. The results of Fig. 5 are consistent with a positive selection of tk in the absence of GCV. It has been shown previously that the balance of the nucleotide pools can influence the growth of HIV-1 (46) . Perhaps the tk encoded on HIV is altering nucleotide pools in favor of efficient viral growth. Furthermore, we expect the generation of escape mutants to occur at a slower rate in vivo because the replication of nef-attenuated virus is severely impaired in vivo and the in vitro replication kinetics are unaffected. Since this virus is also deleted in nef, we expect fewer rounds of replication and thus fewer occasions for the generation of GCV-resistant mutants.
The utility of this vaccine will be determined in the SIV/ Rhesus monkey animal model (30) and the derivation of the model that employs newborns (6). SIV-tk, the molecular cloned virus described here, expresses HSV-1 tk independent of the nef reading frame. We will inoculate SIV-tk into adult Rhesus monkeys. The rate of production of escape mutants will be determined in the presence and absence of GCV treatment, as well as the effect of GCV on the virus load and efficacy. We observed a rather narrow concentration treatment window of GCV concentration in vitro. The effective concentration of GCV observed here in vitro may not predict the effective dose in vivo, especially since the animals will produce an immune response to the virus. We will treat the animals at the maximum tolerable dose.
Viruses deleted in nef replicate to very low levels in the infected adults. The addition of a conditional suicide gene may enable the complete elimination of SIV from the infected individual. The total ablation of lentiviral sequence will require that all compartments harboring virus be eliminated. The elimination of virus from nondividing long-lived cells such as macrophages will be difficult. However, the vaccine strains employed here are T-cell tropic and are unlikely to mutate into macrophage tropic viruses because they are also nef deficient and, thus, will achieve very low virus loads in vivo. Assuming that macrophage tropic variants do arise in vivo, virus production will be blocked during the treatment period and if the treatment window can be extended, so that normal turnover of macrophages, approximately [1] [2] [3] [4] weeks (47, 48) , will lead to attrition of any infected cells. Ultimately, the safety of the live inactivatable vaccine will be determined in the neonate model (6) . The failure of nef-deleted SIV vaccine strains in the newborn may possibly be due to the absence of induction of cellular immunity. The use of SIV-tk followed by GCV treatment will enable the reduction of virus load causing the individual to survive the vaccination and may produce life-long SIV immunity as is observed in the adults.
The biologic properties of AIDS viruses have influenced the design of this vaccine, and ultimately the biology of primate lentiviruses will be responsible for its success or failure. HIV is what Baltimore (49) describes as a nonequlibrium virus, meaning that it is in genetic flux in the human population (49).
An effective vaccine against an evolving target must account for the rapid emergence of antigenic variants in the population. The live nef-attenuated vaccine is, itself, in genetic flux (34) , and the protective response it produces broadens with time (M. Wyand, personal communication). Thus, a live vaccine strain, also being a nonequlibrium virus, will be better able to respond to the emergence of antigenic variants than a static vaccine. The live inactivatable vaccine described here is the first of a new generation of live vaccines. Many improvements and refinements to the combination loss of function with gain of function live vaccine strain are possible. With successive approximations, the goal of a safe effective vaccine for AIDS will be realized.
The vaccine strains described here also have the potential to be tested as a therapeutic vaccine. Since HSV-tk transduction followed by GCV treatment results in the generation of a "bystander effect," where lethality extends beyond the transduced cell to surrounding tissue (21, 22) 
